Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Next Previous
Trial Profile

Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
  • 08 Jan 2016 According to an Advaxis Immunotherapies media release, this trial is expected to commence in the first half of 2016.
  • 01 Dec 2015 According to the Advaxis Inc. media release, the US FDA has granted orphan drug designation for axalimogene filolisbac in the treatment of cervical cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top